DexCom (NASDAQ:DXCM) Given Buy Rating at BTIG Research

DexCom (NASDAQ:DXCM)‘s stock had its “buy” rating reaffirmed by BTIG Research in a research report issued on Monday,Benzinga reports. They presently have a $85.00 target price on the medical device company’s stock. BTIG Research’s target price would indicate a potential upside of 24.82% from the company’s current price.

Several other research analysts have also weighed in on DXCM. Robert W. Baird set a $87.00 target price on shares of DexCom in a research report on Friday, February 13th. Morgan Stanley restated an “overweight” rating on shares of DexCom in a report on Monday, January 12th. Weiss Ratings raised DexCom from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Wednesday. Sanford C. Bernstein reaffirmed an “outperform” rating and set a $86.00 price objective (up from $84.00) on shares of DexCom in a report on Friday, January 9th. Finally, Canaccord Genuity Group set a $95.00 target price on DexCom and gave the stock a “buy” rating in a research report on Friday, February 13th. Two equities research analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating, five have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $85.18.

DexCom Trading Down 3.7%

NASDAQ:DXCM opened at $68.10 on Monday. DexCom has a 1 year low of $54.11 and a 1 year high of $89.98. The company has a debt-to-equity ratio of 0.45, a quick ratio of 1.59 and a current ratio of 1.88. The stock has a fifty day moving average price of $70.69 and a two-hundred day moving average price of $68.75. The stock has a market capitalization of $26.21 billion, a price-to-earnings ratio of 32.43, a PEG ratio of 1.32 and a beta of 1.48.

DexCom (NASDAQ:DXCM) last issued its earnings results on Thursday, February 12th. The medical device company reported $0.68 EPS for the quarter, topping the consensus estimate of $0.65 by $0.03. The company had revenue of $1.26 billion for the quarter, compared to analyst estimates of $1.25 billion. DexCom had a net margin of 17.94% and a return on equity of 32.12%. The business’s revenue was up 13.1% on a year-over-year basis. During the same period in the previous year, the firm earned $0.45 EPS. As a group, sell-side analysts anticipate that DexCom will post 2.03 earnings per share for the current fiscal year.

Institutional Trading of DexCom

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Reflection Asset Management acquired a new stake in shares of DexCom during the 4th quarter worth about $25,000. Andra AP fonden purchased a new stake in shares of DexCom during the second quarter worth about $26,000. Twin Peaks Wealth Advisors LLC acquired a new position in shares of DexCom in the second quarter valued at approximately $26,000. SJS Investment Consulting Inc. raised its position in shares of DexCom by 4,800.0% in the third quarter. SJS Investment Consulting Inc. now owns 392 shares of the medical device company’s stock valued at $26,000 after buying an additional 384 shares during the last quarter. Finally, Financial Consulate Inc. purchased a new position in shares of DexCom during the third quarter valued at approximately $29,000. Hedge funds and other institutional investors own 97.75% of the company’s stock.

About DexCom

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.